Abstract
Previous treatment methods for maxillary sinus carcinoma generally consisted of dissection of maxilla, full dose irradiation, and/or extensive chemotherapy. However, results of such treatment were often poor. Even if patients recover, quality of life (QOL) is significantly reduced as a result of loss of facial structures and functional disability. A retrospective analysis of 42 patients with maxillary sinus carcinoma between 1975 and 1991 was undertaken. All patients underwent pergingival maxillary sinus surgery combined with a standardized total course of pre and postoperative irradiation of 1,600 cGy, together with regional intra-arterial infusion chemotherapy. During the surgery, all visible tumor tissue was removed, and the surrounding tissues were left when possible to facilitate cellular immunity after the surgery. The 5-year survival rate statistically obtained was 100% in Stage II, 100% in Stage III, and 62% in Stage IV patients.
Get full access to this article
View all access options for this article.